Sugi Predict

Sugi Predict / Compounds / SCHEMBL525478

SCHEMBL525478

SCHEMBL525478

C#CC1CCCCN1C(=O)OC(C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ CTSK P43235 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PREP P48147 1/20 0.40
▸ NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10082580 1.00 HPGD (0.50) HPGDHSD17B10CTSKSMN1; SMN2RECQL
SCHEMBL15317053 1.00 HPGD (0.50) HPGDHSD17B10CTSKSMN1; SMN2RECQL
SCHEMBL889059 0.95 HSD17B10 (0.55) HPGDHSD17B10CTSKSMN1; SMN2RECQL
SCHEMBL3188564 0.95 HSD17B10 (0.55) HPGDHSD17B10CTSKSMN1; SMN2RECQL
SCHEMBL231219 0.95 HSD17B10 (0.55) HPGDHSD17B10CTSKSMN1; SMN2RECQL
SCHEMBL1198458 0.92 PTPN2 (0.47) HPGDHSD17B10NPC1
SCHEMBL5275535 0.89 HSD17B10 (0.47) HPGDHSD17B10CTSKSMN1; SMN2RECQL
SCHEMBL4919669 0.89 HSD17B10 (0.47) HPGDHSD17B10CTSKSMN1; SMN2RECQL
SCHEMBL7885175 0.86 HPGD (0.48) HPGDHSD17B10SMN1; SMN2RECQLEPHX1
SCHEMBL7885177 0.86 HPGD (0.48) HPGDHSD17B10SMN1; SMN2RECQLEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof NEWAVE PHARMACEUTICAL INC. (US) 2026-03-10 — — US disclosed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
US-20250122195-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2025-04-17 — — US disclosed
EP-4536642-A1 HETEROCYCLIC COMPOUNDS AS PI3KA INHIBITORS Synnovation Therapeutics, Inc. (US) 2025-04-16 — — EP disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
US-20250073340-A1 SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF NEWAVE PHARMACEUTICAL INC. 2025-03-06 — — US disclosed
US-12195458-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2025-01-14 — — US disclosed
WO-2024129763-A1 MODULATORS OF TNF-α ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2024-06-20 — — WO disclosed
WO-2024129763-A1 MODULATORS OF TNF-α ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2024-06-20 — — WO disclosed
CN-117736182-A MetTL3 inhibitors and uses thereof 成都先导药物开发股份有限公司 2024-03-22 — — CN disclosed
CN-1898238-A Oxazolidinone-quinolone hybrid antibiotics MORPHOCHEM AG FUER KOM (DE) 2007-01-17 — — CN disclosed
WO-2006089311-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2006-08-24 — — WO disclosed
US-20060183745-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2006-08-17 — — US disclosed
EP-1685105-A1 ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharmaceuticals SA (CH) 2006-08-02 — — EP disclosed
WO-2005044797-A1 ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2005-05-19 — — WO disclosed
WO-2005007083-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-01-27 — — WO disclosed
US-20030186995-A1 Substituted bicyclic derivatives useful as anticancer agents PFIZER INC. 2003-10-02 — — US disclosed
US-6541481-B2 A quinazoline compound PFIZER INC 2003-04-01 — — US disclosed
US-20010034351-A1 Substituted bicyclic derivatives useful as anticancer agents KATH JOHN CHARLES (US) 2001-10-25 — — US disclosed
US-6284764-B1 ANTIPROLIFERATIVE AGENT PFIZER INC. 2001-09-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB HPGD 2408/4885HSD17B10 3770/4885CTSK 3070/4885
US-20030186995-A1 Substituted bicyclic derivatives useful as anticancer agents CCNA1, MCL1, RCC1 HPGD 2049/4885HSD17B10 1593/4885CTSK 3137/4885
US-20250122195-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT HPGD 4303/4885HSD17B10 3258/4885CTSK 3590/4885
US-20060183745-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 HPGD 721/4885HSD17B10 2959/4885CTSK 926/4885
US-20250073340-A1 SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF FOXM1, MDM2, FOXO1 HPGD 1572/4885HSD17B10 3512/4885CTSK 2489/4885
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof MDM2, TP53, XIAP HPGD 2935/4885HSD17B10 2871/4885CTSK 2569/4885
US-20010034351-A1 Substituted bicyclic derivatives useful as anticancer agents CCNA1, MCL1, RCC1 HPGD 2049/4885HSD17B10 1593/4885CTSK 3137/4885
US-12195458-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT HPGD 4303/4885HSD17B10 3258/4885CTSK 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.